ReviewMedical science monitor : international medical journal of experimental and clinical research2016
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 294 citations in OpenAlex.
- Urate-lowering effects of losartan: a meta-analysis of randomised controlled trials and target trial emulation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Pooled it
- Association between gout and the risk of osteoporosis and fractures: a meta-analysis.Zeitschrift fur Rheumatologie · 2024Pooled it
- Trial
- Global Trends and Research Hotspots in Natural Products for Hyperuricemia: A Bibliometric Analysis (2004-2026).Pharmaceuticals (Basel, Switzerland) · 2026Review
- Low-level Blood Multiple Metals Exposure from Informal Jewelry Welding Alters Metabolomic and Lipidomic Profiles in Brazilian Women.Biological trace element research · 2026Article
- Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.Journal of nanobiotechnology · 2026Article
- Serum perfluoroalkyl and polyfluoroalkyl substances and the risk of cardiometabolic diseases: Unraveling the mediating role of inflammatory markers.Eco-Environment & Health · 2026Article
- Investigation of the causal effects of hypertension, candesartan, lisinopril, and ramipril on gout.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Bioactive Components, Untargeted Metabolomics and Bioinformatics ofFoods (Basel, Switzerland) · 2025Article
- Association between serum uric acid to albumin ratio and all-cause mortality in critically ill patients with sepsis: a retrospective study.BMC infectious diseases · 2025Article
- A reductive uric acid degradation pathway in anaerobic bacteria.Life metabolism · 2025Article
- Sex-specific associations of preoperative serum uric acid levels with mortality and morbidity in non-cardiac surgeries: a single-center retrospective study.Korean journal of anesthesiology · 2025Article
- Article
- The Molecular Mechanism of Polysaccharides fromFoods (Basel, Switzerland) · 2025Article
- A comprehensive review on anti-inflammatory plants: a mechanistic insight through preclinical and clinical studies.Inflammopharmacology · 2025Review
- Inhibitory Effect of Whey Protein-Derived Peptide Leu-Asp-Gln-Trp on Xanthine Oxidase.Food science & nutrition · 2025Article
- Exploring the Most Effective Strategy for Purine Metabolite Quantification in Veterinary Medicine Using LC-MS/MS.Veterinary sciences · 2025Article
- Probiotic potential ofFrontiers in microbiology · 2025Article
- Shanling Jiangzhi Tea treats hyperuricemia by inhibition of COMT/MAOA signaling pathway and p53/SERPINE1/NLRP3 signaling pathway.Frontiers in endocrinology · 2025Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Uric acid is the final oxidation product of purine metabolism in humans. Xanthine oxidoreductase (XOR) catalyzes oxidative hydroxylation of hypoxanthine to xanthine to uric acid, accompanying the production of reactive oxygen species (ROS). Uric acid usually forms ions and salts known as urates and acid urates in serum. Clinically, overproduction or under-excretion of uric acid results in the elevated level of serum uric acid (SUA), termed hyperuricemia, which has long been established as the major etiologic factor in gout. Accordingly, urate-lowering drugs such as allopurinol, an XOR-inhibitor, are extensively used for the treatment of gout. In recent years, the prevalence of hyperuricemia has significantly increased and more clinical investigations have confirmed that hyperuricemia is an independent risk factor for cardiovascular disease, hypertension, diabetes, and many other diseases. Urate-lowering therapy may also play a critical role in the management of these diseases. However, current XOR-inhibitor drugs such as allopurinol and febuxostat may have significant adverse effects. Therefore, there has been great effort to develop new XOR-inhibitor drugs with less or no toxicity for the long-term treatment or prevention of these hyperuricemia-related diseases. In this review, we discuss the mechanism of uric acid homeostasis and alterations, updated prevalence, therapeutic outcomes, and molecular pathophysiology of hyperuricemia-related diseases. We also summarize current discoveries in the development of new XOR inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.